National Organization for Medicines

National Organization for Medicines
Name	National Organization for Medicines
Native name	Εθνικός Οργανισμός Φαρμάκων
Abbreviation	EOF
Formed	2001
Jurisdiction	Hellenic Republic
Headquarters	Athens, Greece
Parent agency	Ministry of Health
Website	https://www.eof.gr/

National Organization for Medicines. The National Organization for Medicines, known by its Greek acronym EOF, is the national regulatory authority for pharmaceuticals and related products within the Hellenic Republic. Operating under the auspices of the Greek Ministry of Health, it is responsible for ensuring the safety, efficacy, and quality of all medicinal products circulating in the Greek market. Its comprehensive mandate spans from the scientific evaluation of marketing authorizations to the vigilant monitoring of pharmacovigilance and the inspection of manufacturing and distribution facilities.

History and establishment

The organization was formally established in 2001, consolidating and modernizing the country's pharmaceutical regulatory functions which were previously dispersed across various governmental bodies. This creation was part of a broader European Union-driven harmonization of national regulatory frameworks, aligning Greek procedures with the stringent standards of the European Medicines Agency and the broader European Union acquis communautaire. The founding legislation aimed to create a centralized, scientifically robust authority capable of navigating the complexities of modern drug development and global supply chains, replacing older systems that had evolved in the context of the Hellenic State and subsequent post-war administrations.

Legal framework and mission

EOF operates under a robust legal framework primarily defined by national law, which transposes the extensive body of European Union law governing medicinal products for human and veterinary use. Its core mission is to protect public health by ensuring that all medicines available in Greece meet high standards of quality, safety, and efficacy. This mission is executed through rigorous scientific assessment, continuous monitoring, and strict enforcement of regulations, thereby safeguarding patients and healthcare consumers. The organization's mandate is intrinsically linked to the principles enshrined in Directive 2001/83/EC and Regulation (EC) No 726/2004, which establish the community code for medicinal products and the centralized authorization procedure, respectively.

Organizational structure

The agency is headquartered in Athens and is structured into several specialized directorates and departments, each focusing on a critical aspect of the regulatory lifecycle. Key divisions typically include the Directorate of Medicinal Products Assessment, the Directorate of Pharmacovigilance, the Inspectorate Directorate for Good Manufacturing Practice and Good Distribution Practice compliance, and the Directorate of Licensing and Supervision. The organization is led by a President and a Board of Directors, with its scientific committees, such as the Committee for Medicinal Products for Human Use, playing a pivotal advisory role in complex evaluation processes. This structure ensures a multidisciplinary approach, integrating expertise from fields like pharmacology, toxicology, chemistry, and law.

Key functions and responsibilities

EOF's primary functions encompass the national authorization of medicinal products through the decentralized and mutual recognition procedures, as well as participating in the European Medicines Agency's centralized process. It is responsible for the ongoing pharmacovigilance of all marketed drugs, systematically collecting and assessing reports of adverse drug reactions to ensure timely regulatory action. Further key duties include the licensing and inspection of pharmaceutical companies, wholesalers, and pharmacies for compliance with Good Manufacturing Practice and Good Distribution Practice standards. The organization also regulates clinical trials conducted within Greek territory, oversees the safety monitoring of medical devices in coordination with other bodies, and controls the advertising of medicinal products to healthcare professionals and the public.

Regulatory processes and oversight

The regulatory process begins with the meticulous scientific assessment of marketing authorization applications, where dossiers containing data on pharmaceutical quality, non-clinical studies, and clinical trials are reviewed. For post-marketing surveillance, EOF operates a national pharmacovigilance system, often utilizing the EudraVigilance database, to monitor and analyze safety signals. Its inspectorate conducts routine and for-cause inspections at manufacturing sites across Greece and abroad, as well as at wholesale distributors, to verify adherence to quality standards. Enforcement actions can range from issuing warnings and imposing fines to suspending product licenses or recalling batches from the market in collaboration with the European Commission's rapid alert system.

International cooperation

As a member of the European regulatory network, EOF actively collaborates with the European Medicines Agency, the European Commission, and other national competent authorities like the Medicines and Healthcare products Regulatory Agency and the Agence nationale de sécurité du médicament et des produits de santé. It participates in various EU working groups, joint assessments, and inspection initiatives, contributing to the harmonized functioning of the single market for pharmaceuticals. Beyond the European Union, the organization engages with global bodies such as the World Health Organization, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, and the Pharmaceutical Inspection Co-operation Scheme to align with international standards and best practices in pharmaceutical regulation.

Category:Government agencies of Greece Category:Medical and health organisations based in Greece Category:Pharmaceutical policy